Fmr LLC Trims Stake in Ascendis Pharma A/S (NASDAQ:ASND)

FMR LLC lessened its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,728,647 shares of the biotechnology company's stock after selling 179,199 shares during the period. FMR LLC owned 7.79% of Ascendis Pharma A/S worth $650,993,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Y Intercept Hong Kong Ltd bought a new stake in Ascendis Pharma A/S in the third quarter valued at $886,000. Nomura Asset Management Co. Ltd. boosted its stake in shares of Ascendis Pharma A/S by 42.5% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company's stock valued at $2,688,000 after purchasing an additional 5,371 shares in the last quarter. Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S during the third quarter valued at about $60,000. Public Employees Retirement System of Ohio bought a new position in Ascendis Pharma A/S in the third quarter worth about $1,101,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in Ascendis Pharma A/S during the 3rd quarter valued at approximately $19,908,000.

Ascendis Pharma A/S Trading Up 2.4 %

ASND stock traded up $3.66 on Monday, hitting $154.65. The company had a trading volume of 87,946 shares, compared to its average volume of 477,609. The stock has a market cap of $9.43 billion, a price-to-earnings ratio of -21.78 and a beta of 0.54. The stock's 50-day simple moving average is $148.33 and its 200 day simple moving average is $137.63. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $169.37.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. Research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ASND shares. The Goldman Sachs Group lifted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. Cantor Fitzgerald upped their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Finally, Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $204.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.